Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:CATX NASDAQ:ESTA NASDAQ:LQDA NASDAQ:PLSE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCATXPerspective Therapeutics$4.15-4.6%$3.40$1.60▼$16.55$308.05M1.18981,314 shs444,476 shsESTAEstablishment Labs$43.15-0.1%$39.65$26.56▼$50.85$1.25B0.8342,531 shs307,836 shsLQDALiquidia Technologies$18.77+5.7%$14.84$8.26▼$19.41$1.52B-0.012.20 million shs3.30 million shsPLSEPulse Biosciences$14.87-2.0%$16.11$13.50▼$25.00$1.02B1.56162,242 shs95,488 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCATXPerspective Therapeutics+1.16%+6.62%+5.84%+79.75%-66.41%ESTAEstablishment Labs-0.67%-1.10%+18.04%+44.95%-10.06%LQDALiquidia Technologies+6.93%+25.09%+33.86%+26.51%+53.68%PLSEPulse Biosciences+0.07%-3.50%-2.07%-21.28%-13.07%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCATXPerspective Therapeutics1.9849 of 5 stars4.61.00.00.00.60.80.0ESTAEstablishment Labs2.0728 of 5 stars3.41.00.00.01.52.50.6LQDALiquidia Technologies3.2872 of 5 stars4.50.00.00.01.94.20.6PLSEPulse Biosciences3.4936 of 5 stars3.50.00.04.20.04.20.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCATXPerspective Therapeutics 3.18Buy$12.56202.54% UpsideESTAEstablishment Labs 2.83Moderate Buy$54.8327.08% UpsideLQDALiquidia Technologies 3.00Buy$26.8943.25% UpsidePLSEPulse Biosciences 3.00Buy$22.0047.95% UpsideCurrent Analyst Ratings BreakdownLatest CATX, LQDA, ESTA, and PLSE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/16/2025ESTAEstablishment LabsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$58.00 ➝ $70.007/12/2025CATXPerspective TherapeuticsLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy7/9/2025ESTAEstablishment LabsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$38.00 ➝ $47.007/7/2025PLSEPulse BiosciencesOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$22.006/23/2025CATXPerspective TherapeuticsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $12.006/23/2025CATXPerspective TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$11.006/13/2025ESTAEstablishment LabsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$48.006/12/2025LQDALiquidia TechnologiesWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$23.00 ➝ $25.006/11/2025LQDALiquidia TechnologiesBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$25.00 ➝ $23.006/3/2025CATXPerspective TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeOutperform ➝ Moderate Buy$15.00 ➝ $16.006/2/2025LQDALiquidia TechnologiesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy(Data available from 7/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCATXPerspective TherapeuticsN/AN/AN/AN/A$2.67 per shareN/AESTAEstablishment Labs$166.02M7.52N/AN/A$1.90 per share22.71LQDALiquidia Technologies$14M114.62N/AN/A$0.91 per share20.63PLSEPulse BiosciencesN/AN/AN/AN/A$1.87 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCATXPerspective Therapeutics-$46.51MN/A0.00N/AN/A-4,096.66%-27.40%-23.16%8/13/2025 (Estimated)ESTAEstablishment Labs-$84.60M-$3.10N/AN/AN/A-52.34%-196.25%-26.64%8/5/2025 (Estimated)LQDALiquidia Technologies-$130.39M-$1.58N/AN/AN/A-903.80%-177.91%-60.15%8/6/2025 (Estimated)PLSEPulse Biosciences-$53.58MN/A0.00∞N/AN/A-68.44%-58.17%8/14/2025 (Estimated)Latest CATX, LQDA, ESTA, and PLSE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025PLSEPulse Biosciences-$0.26N/AN/AN/AN/AN/A8/13/2025N/ACATXPerspective Therapeutics-$0.30N/AN/AN/A$0.17 millionN/A8/6/2025Q2 2025LQDALiquidia Technologies-$0.43N/AN/AN/A$3.90 millionN/A8/5/2025Q2 2025ESTAEstablishment Labs-$0.54N/AN/AN/A$50.80 millionN/A5/8/2025Q1 2025LQDALiquidia Technologies-$0.42-$0.45-$0.03-$0.45$3.23 million$3.12 million5/8/2025Q1 2025PLSEPulse BiosciencesN/A-$0.25N/A-$0.25N/AN/A5/7/2025Q1 2025ESTAEstablishment Labs-$0.83-$0.70+$0.13-$0.70$41.15 million$41.38 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCATXPerspective TherapeuticsN/AN/AN/AN/AN/AESTAEstablishment LabsN/AN/AN/AN/AN/ALQDALiquidia TechnologiesN/AN/AN/AN/AN/APLSEPulse BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCATXPerspective TherapeuticsN/A9.609.60ESTAEstablishment Labs5.723.362.05LQDALiquidia Technologies2.082.932.91PLSEPulse BiosciencesN/A15.5815.58Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCATXPerspective Therapeutics54.66%ESTAEstablishment Labs72.91%LQDALiquidia Technologies64.54%PLSEPulse Biosciences76.95%Insider OwnershipCompanyInsider OwnershipCATXPerspective Therapeutics3.72%ESTAEstablishment Labs11.09%LQDALiquidia Technologies26.50%PLSEPulse Biosciences71.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCATXPerspective Therapeutics7074.23 million65.21 millionOptionableESTAEstablishment Labs1,01828.92 million25.71 millionOptionableLQDALiquidia Technologies5085.49 million62.83 millionOptionablePLSEPulse Biosciences14067.27 million19.17 millionOptionableCATX, LQDA, ESTA, and PLSE HeadlinesRecent News About These CompaniesPulse Biosciences (NASDAQ:PLSE) Stock Price Down 5.9% - Time to Sell?July 11, 2025 | marketbeat.comOppenheimer Initiates Coverage of Pulse Biosciences (PLSE) with Outperform RecommendationJuly 8, 2025 | msn.comPulse Biosciences (NASDAQ:PLSE) Stock Price Up 5.6% - Here's What HappenedJuly 7, 2025 | marketbeat.comOppenheimer Begins Coverage on Pulse Biosciences (NASDAQ:PLSE)July 7, 2025 | marketbeat.comPulse Biosciences (NASDAQ:PLSE) Stock Price Down 3.4% - Here's WhyJuly 3, 2025 | marketbeat.comInsider Purchases Worth US$2.70m See Losses As Pulse Biosciences Market Value Drops To US$1.1bJune 17, 2025 | finance.yahoo.comPulse Biosciences, Inc. (NASDAQ:PLSE) CTO Darrin Uecker Sells 15,000 SharesJune 17, 2025 | insidertrades.comPulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 23, 2025 | businesswire.comPulse Biosciences, Inc. (NASDAQ:PLSE) insiders have significant skin in the game with 73% ownershipMay 21, 2025 | uk.finance.yahoo.comPulse Biosciences, Inc. (PLSE) Q1 2025 Earnings Call TranscriptMay 10, 2025 | seekingalpha.comPulse Biosciences To Present at the BofA Securities 2025 Health Care ConferenceMay 6, 2025 | businesswire.comPulse Biosciences’ Nanosecond PFA Technology to be Featured at The American Association for Thoracic Surgery 2025 Annual MeetingMay 2, 2025 | finance.yahoo.comPulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 25, 2025 | businesswire.comPulse Biosciences (NASDAQ:PLSE) Is In A Strong Position To Grow Its BusinessApril 24, 2025 | finance.yahoo.comPulse Biosciences Schedules First Quarter 2025 Financial Results Conference Call for May 8, 2025April 24, 2025 | businesswire.comPulse Biosciences’ Nanosecond PFA Technology to be Featured at The Heart Rhythm Society 2025 Annual MeetingApril 23, 2025 | finance.yahoo.comPulse Biosciences: Some Key Questions Remain UnansweredApril 10, 2025 | seekingalpha.comPulse Biosciences: Interesting Product, But No Revenue StreamApril 10, 2025 | seekingalpha.comEarnings call transcript: Pulse Biosciences Q4 2024 misses EPS, stock risesMarch 29, 2025 | investing.comPulse Biosciences, Inc. (NASDAQ:PLSE) Q4 2024 Earnings Call TranscriptMarch 29, 2025 | insidermonkey.comPulse Biosciences reports wider Q4 loss, shares dipMarch 27, 2025 | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesChipotle: Too Spicy for Smart Money to Resist After Stock SplitBy Jeffrey Neal Johnson | July 11, 2025View Chipotle: Too Spicy for Smart Money to Resist After Stock SplitIs China Investable Again? 2 Stocks Soaring as Tensions EaseBy Dan Schmidt | July 21, 2025View Is China Investable Again? 2 Stocks Soaring as Tensions EaseBuybacks Galore: Repurchases From the Oval Office to Olive GardenBy Leo Miller | June 30, 2025View Buybacks Galore: Repurchases From the Oval Office to Olive GardenWhy Prologis May Be the Smartest Backdoor Bet on AI Real EstateBy Chris Markoch | July 17, 2025View Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate3 Fast Food Stocks That Won’t Give You Indigestion Right NowBy Brian O'Connell | July 16, 2025View 3 Fast Food Stocks That Won’t Give You Indigestion Right NowCATX, LQDA, ESTA, and PLSE Company DescriptionsPerspective Therapeutics NYSE:CATX$4.15 -0.20 (-4.60%) Closing price 04:00 PM EasternExtended Trading$4.21 +0.06 (+1.42%) As of 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.Establishment Labs NASDAQ:ESTA$43.15 -0.03 (-0.07%) Closing price 04:00 PM EasternExtended Trading$43.92 +0.77 (+1.78%) As of 06:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander. The company sells its products to physicians, hospitals, and clinics through distributors and direct sales force in Europe, the Middle East, Latin America, and Asia. Establishment Labs Holdings Inc. was incorporated in 2004 and is headquartered in Alajuela, Costa Rica.Liquidia Technologies NASDAQ:LQDA$18.77 +1.02 (+5.75%) Closing price 04:00 PM EasternExtended Trading$18.52 -0.25 (-1.33%) As of 07:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.Pulse Biosciences NASDAQ:PLSE$14.87 -0.30 (-1.98%) Closing price 04:00 PM EasternExtended Trading$14.89 +0.02 (+0.13%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Krispy Kreme: A Meme Stock Sugar Rush or a Sustainable Treat? From Zero to Hero? Why GoPro's Rally Could Be More Than It Seems A Smokin’ Hot Entry Point for Chipotle Stock Opens in Q3 Alphabet’s Breakout Quarter Signals a New Leadership Phase Tesla Just Hit a Fork in the Road—Could the Bulls Lose Control? GE Vernova's Q2 Electrifies Stock, What's Next For This Top Name? Is Former Dividend Aristocrat AT&T a Buy After Q2 Earnings? What's Behind Opendoor Technologies' Rally? Is Meme Mania Back? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
